Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EISAI CO

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1941-12-06

Employees: 11K

Market Cap: $12B

Website: http://www.eisai.co.jp

Clinical Trials

A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy

Completed

Conditions: Partial-onset Seizures
Epilepsy

Interventions: Drug: Perampanel

First Posted Date: 2020-01-18

Last Posted Date: 2020-01-18

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 117

Registration Number: NCT04230044

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1

Active, not recruiting

Conditions: Solid Neoplasms

Interventions: Drug: E7389-LF
Drug: Nivolumab

First Posted Date: 2019-09-06

Last Posted Date: 2024-12-10

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 125

Registration Number: NCT04078295

Locations: 🇯🇵
Eisai Trial Site #11, Akashi, Hyogo, Japan
🇯🇵
Eisai Trial Site #18, Kashiwa City, Chiba, Japan
🇯🇵
Eisai Trial Site #2, Kashiwa, Chiba, Japan

and more 16 locations

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Completed

Conditions: Carcinoma
Neoplasms, Glandular and Epithelial
Carcinoma, Hepatocellular
Neoplasms

Interventions: Drug: Lenvatinib

First Posted Date: 2019-07-05

Last Posted Date: 2022-03-08

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 412

Registration Number: NCT04008082

Locations: 🇯🇵
Eisai Trial Site #2, Tokyo, Japan
🇯🇵
Eisai Trial Site #1, Osaka, Japan

A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: E0302 SR1
Drug: E0302 SR3
Drug: E0302 SR2
Drug: E0302 IR

First Posted Date: 2019-03-22

Last Posted Date: 2019-12-24

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT03885882

Locations: 🇳🇿
Auckland Clinical Studies, Auckland, New Zealand

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Phase 1

Active, not recruiting

Conditions: Gastrointestinal Tumors
Colorectal Neoplasms
Solid Neoplasms

Interventions: Drug: E7386

First Posted Date: 2019-02-07

Last Posted Date: 2025-01-15

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 70

Registration Number: NCT03833700

Locations: 🇯🇵
Eisai Trial Site#8, Sendai, Miyagi, Japan
🇯🇵
Eisai Trial Site #5, Sapporo, Hokkaido, Japan
🇯🇵
Eisai Trial Site #4, Fukuoka, Japan

and more 5 locations

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: E2007
Drug: Placebo

First Posted Date: 2018-12-19

Last Posted Date: 2018-12-19

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT03780907

Locations: 🇩🇪
3ClinicalResearch AG, Hennigsdorf, Germany

A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

Phase 2

Completed

Conditions: Epilepsy
Seizures

Interventions: Drug: Perampanel

First Posted Date: 2018-11-27

Last Posted Date: 2021-01-05

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 21

Registration Number: NCT03754582

Locations: 🇯🇵
Eisai trial site 9, Omura, Nagasaki, Japan
🇯🇵
Eisai trial site 10, Hiroshima, Japan
🇯🇵
Eisai trial site 4, Yamagata, Japan

and more 10 locations

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: methylcobalamin
Drug: saline solution

First Posted Date: 2018-06-07

Last Posted Date: 2025-03-26

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT03548311

Locations: 🇯🇵
Chiba University Hospital, Chiba, Japan
🇯🇵
Okayama University Hospital, Okayama, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan

and more 13 locations

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Phase 2

Completed

Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Interventions: Drug: Tazemetostat

First Posted Date: 2018-03-07

Last Posted Date: 2022-12-16

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT03456726

Locations: 🇯🇵
1028 Eisai Trial Site, Yokohama, Kanagawa, Japan
🇯🇵
1001 Eisai Trial Site, Chuo-ku, Tokyo, Japan
🇯🇵
1011 Eisai Trial Site, Hiroshima, Japan

and more 25 locations

A Study of E7130 in Participants With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: E7130

First Posted Date: 2018-02-23

Last Posted Date: 2025-03-06

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 62

Registration Number: NCT03444701

Locations: 🇯🇵
Eisai Trial Site 9, Nagoya, Aichi, Japan
🇯🇵
Eisai Trial Site 8, Sapporo, Hokkaido, Japan
🇯🇵
Eisai Trial Site 4, Sendai, Miyagi, Japan

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy